The Acute Myeloid Leukemia Channel on VJHemOnc is an independent medical education platform, supported with funding from BMS (Silver), and through an educational grant from Jazz Pharmaceuticals. Supporters have no influence on the production of content. The levels of sponsorship listed are reflective of the amount of funding given.
ISAL 2019 | MRD detection for AML in China & MFC to detect CEPBA mutations
Measurable residual disease (MRD) monitoring can be performed using a number of methods, including multiparametric flow cytometry (MFC) and PCR. We spoke to Hong-Hu Zhu, MD, PhD, of The First Affiliated Hospital, Zhejiang University, Hangzhou, China, about the use of MRD measurement in China, as well as his recent research intro the use of MFC to detect MRD in acute myeloid leukemia (AML) with CEBPA mutations. This interview took place at the International Symposium on Acute Leukemias (ISAL) 2019, held in Munich, Germany.
